#USA #Sanford #Diagnostic Imaging #Bracco #Contrast Media

Bracco's Major Investment in U.S. Manufacturing

Bracco, a trusted leader in the diagnostic imaging sector, has unveiled plans for a significant $230 million investment, aiming to establish its inaugural manufacturing facility in the United States dedicated to injectable contrast media. Located in Sanford, North Carolina, this cutting-edge facility is set to enhance Bracco's manufacturing capabilities while bolstering the resilience of the supply chain in the health care sector, which has been increasingly challenged in recent years.

Fulvio Renoldi Bracco, the Vice Chairman and CEO, emphasized the paramount importance of this investment in the context of Bracco's long-standing commitment to improving patient outcomes. “For almost 100 years, Bracco has been committed to enhancing people's lives. The U.S. is not only our largest market but also home to countless patients relying on our products,” he stated. The decision to feel the pulse of the U.S. market by establishing the plant in North Carolina highlights their strategic vision of positioning themselves closer to American hospitals and the patients they serve.

This facility is anticipated to stimulate local economic growth by creating approximately 200 new jobs across various domains such as manufacturing, engineering, quality control, warehousing, and administrative roles. The investment reflects Bracco's dedication to permanent contributions to the Sanford community and importantly, supports the growth of North Carolina's life sciences sector.

Recognizing North Carolina's rich talent pool and its robust life sciences ecosystem, Bracco's choice underscores a strategic commitment to nurturing local partnerships as they expand operations. This facility is designed to feature top-tier sterile manufacturing processes that align with the high standards for quality that Bracco is known for globally. By enhancing the existing framework in another strategic location, Bracco aims to create a more diversified and resilient manufacturing network that spans across North America, Europe, and Asia.

This development is emblematic of Bracco's extensive history of innovation that began nearly a century ago. Its long-standing focus on advancing technologies for diagnostic imaging puts them in a crucial position to meet and adapt to the ever-growing demands in healthcare, particularly in diagnostic imaging, where reliable access to injectable contrast media is essential.

Bracco also maintains a robust commitment to research and development, channeling about 9% of their annual turnover into enhancing imaging technologies and solutions. Their extensive portfolio of diagnostic imaging products includes contrast agents for various imaging methods such as X-ray, CT scans, and MRIs, bolstering Bracco’s role as a key player in the healthcare landscape.

In summary, Bracco's investment highlights their strategic intentions to not only fortify their market position but also invest in the community that supports their operations. This project will allow Bracco to maintain its competitive edge while simultaneously contributing to the local economy, thus fostering a future-ready healthcare environment. With this move, Bracco continues its storied legacy of innovation while setting a benchmark for the industry in the United States.